ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a specialist in liquid biopsy, announced a significant advancement in cancer diagnostics, offering more personalized and actionable insights into the disease and its progression.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma (MTPH), an R&D biotechnology company, said that Rolf Stahel, Chairman and non-executive director, intends to retire after the company’s AGM on 20 June 2022.
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM